匹多莫德与利巴韦林联合治疗儿童手足口病的临床观察

Efficacy of Pidotimod plus Ribavirin for Hand-foot-mouth Disease in Children

目的:探讨匹多莫德与利巴韦林联合治疗儿童手足口病的临床疗效。方法:将2012年7月—2013年12月收治的130例手足口病患儿,以抽签法随机分为观察组与对照组各65例。对照组患儿给予利巴韦林治疗,观察组患儿在利巴韦林的基础上给予匹多莫德联合治疗。治疗1周后,比较2组患儿的治疗效果。结果:治疗后,观察组患儿的皮疹、溃破、发热消退时间和痊愈时间均明显短于对照组,差异有统计学意义(P<0.05);观察组患儿的总有效率为100.00%(65/65),明显高于对照组的83.08%(54/65),差异有统计学意义。结论:临床治疗儿童手足口病时,采用匹多莫德与利巴韦林联合治疗,能有效提高治疗效果。

OBJECTIVE： To investigate the clinical efficacy of ribavirin plus pidotimod for hand-foot-mouth disease in children. METHODS： 130 children with hand-foot-mouth disease treated in our hospital between July 2012 and December 2013 were randomly divided into observation group and control group of 65 cases each. The control group was given ribavirin alone while the observation group given pidotimod plus ribavirin. The therapeutic efficacy at one week of treatment was compared between the two groups. RESULTS： The subsidence time of rash,ulceration and fever and the recovery time in the observation group were significantly shorter than in the control group,and the differences were statistically significant（ P〈0. 05）; the total response rate in the observation group was significantly higher in the observation group than in the control group[100. 00%（ 65 /65） vs. 83. 08%（ 54 /65）,and the differences were statistically significant. CONCLUSIONS： Addition of pidotimod to ribavirin results in better efficacy for hand-footmouth disease in children.